Company Analysis
Sign in

Biogen Inc. (BIIB)

Nasdaq: BIIB · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 1996
Full chart Alerts Compare
Grade5.9
◀ Past 6.4● Present 6.7▶ Future 4.4
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$9.89B+2.2%
Net income$1.29B-20.8%
Earnings per share$8.79-21.4%
Operating cash flow$2.20B-23.3%
Cash$3.01B+26.7%
Debt$6.29B-0.1%
Shareholders’ equity$18.26B+9.2%
Shares, diluted147.1M+0.8%
Return on equity7.1%
The recordfrom its filings
Filings in 202679
Newest filingNov 10 · SCHEDULE 13G
Annual reportFeb 6, 2026
Quarterly reportOct 28, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$900,000
Insider buys, 12 months$0.00
Patents granted606
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $10.30BNet income $348MCash from operations $2.25Bthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

The company now

Biogen reported third-quarter 2026 revenue of $2.8 billion on October 28, 2026, up 11% from a year earlier 1.

Growth products drove it: that group brought in $1.26 billion, up 49%, including the first full quarter of the Apellis medicines SYFOVRE and EMPAVELI 1.

Multiple sclerosis (MS) sales, the older core business, fell 13% to $919 million 1.

The company's GAAP loss of $0.14 a share was driven mainly by transaction-related charges, and it raised the low end of its 2026 non-GAAP earnings guidance to a range of $12.20 to $13.00 1.

Reuters reported that revenue topped the $2.63 billion LSEG estimate 4.

Next, the company expects top-line results from two Phase 3 studies of litifilimab in lupus in the first half of December 2026 1.

As of Nov 3, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

News

Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Nov 2, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 28, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Oct 28, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 5, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 3, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 5, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton BIIB · research, not advice